1. Scrip

Otsuka Looks To New Products As Abilify Plunge Bites

 
• By Ian Haydock

Otsuka has added some flesh to the bones of its strategy to fill the hole left by plunging sales of mainstay product Abilify due to generic competition, with new formulations of the atypical antipsychotic and pipeline CNS drugs seen as driving growth over the next few years.

TOKYO - Following loss of exclusivity and the advent of its first US generic competition in April, Otsuka Holdings Co. Ltd.'s atypical antipsychotic Abilify (aripiprazole) saw its North American sales in the six months ended June 30 plunge 37% in dollar terms to $1.46bn.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia